Fluacizine

Jump to: navigation, search
Fluacizine
File:Fluacizine structure.svg
Clinical data
SynonymsFlouracizine, Phtorazisin, ftoracizin, 10-(3-(Diethylamino)propionyl)
-2-(trifluoromethyl)phenothiazine, 2-(Trifluoromethyl)-10-
(N,N-diethyl-beta-alanyl)phenothiazine
Routes of
administration
Oral, intramuscular
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC20H21F3N2OS
Molar mass394.455 g/mol
3D model (JSmol)

Fluacizine (INN) is an antidepressant with sedative properties derived from phenothiazine.

Fluacizine possesses strong central and peripheral anticholinergic activity.

Uses

Approved

Fluacizine is indicated in bipolar depression, the emotional problems accompanying schizophrenia, anxiety accompanying depression, and for the depressive and extrapyramidal symptoms resulting from neuroleptic therapy. It is not effective for atypical depression or late-onset depression (once known as involutional melancholia).

Side effects

Side effects of fluacizine include feeling of weakness, nausea, and dry mouth.

Contraindications

Fluacizine is contraindicated in patients with liver or kidney impairment, enlarged prostate, peptic ulcer or who have taken MAOIs less than 14 days before starting therapy. la:Fluacizinum


Linked-in.jpg